/ Browse·page 1624 of 1630

Browse EX-10 agreements

19,554 total material contract exhibits.

Filters

CEO PSU Award

Keenova Therapeutics plc

2025 Stock and Incentive Plan (“Plan”)

TERMS AND CONDITIONS OF PERFORMANCE RESTRICTED UNIT AWARD

PERFORMANCE RESTRICTED UNIT AWARD (“Award”) granted on _______, 202__ (the “Grant Date”).

1.Grant of Performance Restricted Units. Keenova Therapeutics plc (the “Company”) has granted to you a target number of [____] Performance Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Company will hold the Performance Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Performance Restricted Unit represents one (1) Ordinary Share and any Performance Restricted Units that vest pursuant to Section 4 will be paid solely in Shares, subject to Section 11. Notwithstanding anything contrary in the Plan, any fractional Shares will be rounded up to the nearest whole Share for purposes of payment. Any Share issued pursuant to a Performance Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

3.Dividends. Each unvested Performance Restricted Unit will be credited with a Dividend Equivalent Unit (“DEU”) for any cash or stock dividends distributed by the Company on an Ordinary Share. DEUs will be calculated at the same dividend rate paid to other holders of Ordinary Shares and will be adjusted and vest in accordance with the adjustment and vesting provisions applicable to the underlying Performance Restricted Units.

…

Open document
EX-10.19·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

CEO RSU Award

Keenova Therapeutics plc

2025 Stock and Incentive Plan (“Plan”)

TERMS AND CONDITIONS

OF

RESTRICTED UNIT AWARD

RESTRICTED UNIT AWARD (“Award”) granted on _______, 202__ (the “Grant Date”).

1.Grant of Restricted Units. Keenova Therapeutics plc (the “Company”) has granted you [____] Restricted Units subject to the provisions of these Terms and Conditions and the Plan. [____] of the Restricted Units constitute the “Founders Grant” as set forth in that certain Fourth Amended and Restated Employment Agreement entered into on February 23, 2026 by and between you and ST Shared Services LLC (the “Employment Agreement”). The Company will hold the Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Restricted Unit represents one (1) Ordinary Share and vested Restricted Units will be paid solely in Shares, subject to Section 10. Any Share issued pursuant to a Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

…

Open document
EX-10.18·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

Director RSU Award

Keenova Therapeutics plc

2025 Stock and Incentive Plan (“Plan”)

TERMS AND CONDITIONS

OF

RESTRICTED UNIT AWARD

RESTRICTED UNIT AWARD (“Award”) granted on _______, 202__ (the “Grant Date”).

1.Grant of Restricted Units. Keenova Therapeutics plc (the “Company”) has granted you [____] Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Company will hold the Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Restricted Unit represents one (1) Ordinary Share and vested Restricted Units will be paid solely in Shares, subject to Section 10. Any Share issued pursuant to a Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

3.Dividends. Each unvested Restricted Unit will be credited with a Dividend Equivalent Unit (“DEU”) for any cash or stock dividends distributed by the Company on an Ordinary Share. DEUs will be calculated at the same dividend rate paid to other holders of Ordinary Shares and will be adjusted and vest in accordance with the adjustment and vesting provisions applicable to the underlying Restricted Units and shall be paid as of the same date payment for the Restricted Units occurs.

…

Open document
EX-10.17·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

[CFO Inducement Grant]

Mallinckrodt Pharmaceuticals

2025 Stock and Incentive Plan (“Plan”)

TERMS AND CONDITIONS

OF

RESTRICTED UNIT AWARD

RESTRICTED UNIT AWARD (“Award”) granted on September 23, 2025 (the “Grant Date”).

1.Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you 91,007 Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Company will hold the Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Restricted Unit represents one (1) Ordinary Share and vested Restricted Units will be paid solely in Shares, subject to Section 10. Any Share issued pursuant to a Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

3.Dividends. Each unvested Restricted Unit will be credited with a Dividend Equivalent Unit (“DEU”) for any cash or stock dividends distributed by the Company on an Ordinary Share. DEUs will be calculated at the same dividend rate paid to other holders of Ordinary Shares and will be adjusted and vest in accordance with the adjustment and vesting provisions applicable to the underlying Restricted Units and shall be paid as of the same date payment for the Restricted Units occurs.

…

Open document
EX-10.16·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

[CEO Inducement Grant]

Mallinckrodt Pharmaceuticals

2025 Stock and Incentive Plan (“Plan”)

Terms and Conditions

of

Restricted Unit Award

RESTRICTED UNIT AWARD (“Award”) granted on August 14, 2025 (the “Grant Date”).

1.Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you 65,005 Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Company will hold the Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Restricted Unit represents one (1) Ordinary Share and vested Restricted Units will be paid solely in Shares, subject to Section 10. Any Share issued pursuant to a Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

3.Dividends. Each unvested Restricted Unit will be credited with a Dividend Equivalent Unit (“DEU”) for any cash or stock dividends distributed by the Company on an Ordinary Share. DEUs will be calculated at the same dividend rate paid to other holders of Ordinary Shares and will be adjusted and vest in accordance with the adjustment and vesting provisions applicable to the underlying Restricted Units and shall be paid as of the same date payment for the Restricted Units occurs.

…

Open document
EX-10.15·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

[Director Form]

Mallinckrodt Pharmaceuticals2025 Stock and Incentive Plan (“Plan”)

Terms and Conditions of Restricted Unit Award

RESTRICTED UNIT AWARD (“Award”) granted on _______, 202__ (the “Grant Date”).

1.Grant of Restricted Units. Mallinckrodt plc (the “Company”) has granted you [____] Restricted Units subject to the provisions of these Terms and Conditions and the Plan. The Company will hold the Restricted Units in a bookkeeping account on your behalf until such units become payable or are forfeited or cancelled.

2.Amount and Form of Payment. Each Restricted Unit represents one (1) Ordinary Share and vested Restricted Units will be paid solely in Shares, subject to Section 10. Any Share issued pursuant to a Restricted Unit shall be paid up to its par value on issuance by a subsidiary of the Company or as otherwise determined by the Company.

3.Dividends. Each unvested Restricted Unit will be credited with a Dividend Equivalent Unit (“DEU”) for any cash or stock dividends distributed by the Company on an Ordinary Share. DEUs will be calculated at the same dividend rate paid to other holders of Ordinary Shares and will be adjusted and vest in accordance with the adjustment and vesting provisions applicable to the underlying Restricted Units and shall be paid as of the same date payment for the Restricted Units occurs.

…

Open document
EX-10.14·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

ENDO, INC. PERFORMANCE AWARD NOTICE UNDER THE 2024 STOCK INCENTIVE PLAN

This Performance Award Notice, which shall include the Performance Award Grant Notice and the Terms and Conditions (collectively, the “Award Notice”) is being provided to the participant (the “Participant”) by Endo, Inc. (the “Company”) as of the date of grant set forth below (the “Date of Grant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the version of the Endo, Inc. 2024 Stock Incentive Plan as in effect on the Date of Grant, as specified below (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.

1


ENDO, INC. PERFORMANCE AWARD NOTICE UNDER THE 2024 STOCK INCENTIVE PLAN PERFORMANCE AWARD GRANT NOTICE

Name of Participant: [ ]
Total Number of Restricted Stock Units Underlying the Performance Award (at Target): [ ]
Date of Grant: [ ]
Vesting Date: [ ]

2


ENDO, INC. PERFORMANCE AWARD NOTICE UNDER THE 2024 STOCK INCENTIVE PLAN TERMS AND CONDITIONS

Note, Sections 1 through 24 of this Award Notice reflect general terms and, as applicable, are modified by Section 25 with respect to the laws of any country or jurisdiction where the Participant’s awards are granted.

…

Open document
EX-10.13·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

ENDO, INC. STOCK AWARD NOTICE UNDER THE 2024 STOCK INCENTIVE PLAN (EMPLOYEE FORM)

This Stock Award Notice (this “Award Notice”) is being provided to the participant (the “Participant”) by Endo, Inc. (the “Company”) as of the date of grant set forth below (the “Date of Grant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the version of the Endo, Inc. 2024 Stock Incentive Plan as in effect on the Date of Grant (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.

Name of Participant: [ ]
Number of Stock Awards: [ ]
Date of Grant: [ ]
Vesting Dates: [ ]

Note, Sections 1 through 24 of this Award Notice reflect general terms and, as applicable, are modified by Section 25 with respect to the laws of any country or jurisdiction where the Participant’s awards are granted.

1.Grant of Stock Awards. The Company hereby grants to the Participant the total number of restricted stock units set forth above (the “Stock Awards”), subject to all of the terms and conditions of this Award Notice and the Plan.

2.Form of Payment and Vesting.

…

Open document
EX-10.12·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

First Lien Intercreditor Agreement Supplement

SUPPLEMENT NO. 6 dated as of March 13, 2026 (this “Supplement”), to the FIRST LIEN INTERCREDITOR AGREEMENT dated as of April 23, 2024 (the “First Lien Intercreditor Agreement”), among Endo LP (f/k/a Endo, Inc.) (“Holdings”), Endo Finance Holdings LP (f/k/a Endo Finance Holdings, Inc.) (“Borrower”), the other Grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the Credit Agreement Secured Parties (in such capacity and together with its successors in such capacity, the “Bank Collateral Agent”), and Computershare Trust Company, National Association, as collateral agent for the Indenture Secured Parties (in such capacity and together with its successors in such capacity, the “Notes Collateral Agent”), and each Additional Agent from time to time party thereto.

A    Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the First Lien Intercreditor Agreement.

B.    The Grantors have entered into the First Lien Intercreditor Agreement. Section 5.16 of the First Lien Intercreditor Agreement provides that Subsidiaries may become party to the First Lien Intercreditor Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Subsidiaries listed on Schedules I and II attached hereto (each a “New Grantor” and, if multiple, collectively the “New Grantors”) are each executing this Supplement in accordance with the requirements of the Credit Agreement, the Indenture and the Additional First Lien Documents.

…

Open document
EX-10.11·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

First Lien Intercreditor Agreement Supplement

SUPPLEMENT NO. 5 dated as of March 5, 2026 (this “Supplement”), to the FIRST LIEN INTERCREDITOR AGREEMENT dated as of April 23, 2024 (the “First Lien Intercreditor Agreement”), among Endo LP (f/k/a Endo, Inc.) (“Holdings”), Endo Finance Holdings LP (f/k/a Endo Finance Holdings, Inc.) (“Borrower”), the other Grantors party thereto, Goldman Sachs Bank USA, as collateral agent for the Credit Agreement Secured Parties (in such capacity and together with its successors in such capacity, the “Bank Collateral Agent”), and Computershare Trust Company, National Association, as collateral agent for the Indenture Secured Parties (in such capacity and together with its successors in such capacity, the “Notes Collateral Agent”), and each Additional Agent from time to time party thereto.

A    Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the First Lien Intercreditor Agreement.

B.    The Grantors have entered into the First Lien Intercreditor Agreement. Section 5.16 of the First Lien Intercreditor Agreement provides that Subsidiaries may become party to the First Lien Intercreditor Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Subsidiaries listed on Schedules I and II attached hereto (each a “New Grantor” and, if multiple, collectively the “New Grantors”) are each executing this Supplement in accordance with the requirements of the Credit Agreement, the Indenture and the Additional First Lien Documents.

…

Open document
EX-10.10·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

ENDO USA, INC.

EXECUTIVE EMPLOYMENT AGREEMENT

THIS AGREEMENT (this “Agreement”) is hereby effective as of May 10, 2024 (the “Effective Date”), by and between Endo USA, Inc. (the “Company”), a wholly-owned subsidiary of Endo, Inc. (“Endo”), and Mark Bradley (“Executive”) (hereinafter collectively referred to as “the parties”).

In consideration of the respective agreements of the parties contained herein, it is agreed as follows:

1.Term. Executive’s employment with the Company under the terms and conditions of this Agreement will commence on the Effective Date and will continue until the termination of Executive’s employment with the Company (the “Employment Term”).

2.Employment. During the Employment Term:

(a)Executive shall serve as Executive Vice President and Chief Financial Officer of Endo and shall be assigned with the customary duties and responsibilities of such position.

(b)Executive shall report directly to the Chief Executive Officer of Endo. Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in a similar executive capacity.

…

Open document
EX-10.8·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT

FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on February 28, 2024 (the “Effective Date”) by and between Mallinckrodt Pharmaceuticals Ireland Ltd., an Irish limited liability company, or any successor thereto (the “Company”), and Paul O’Neill (the “Executive”) (collectively referred to as “Parties” or individually referred to as a “Party”).

WHEREAS, the Executive was previously party to an Employment Agreement, dated January 18, 2023, by and between the Company and the Executive, as subsequently amended on March 9, 2023 (the “Prior Agreement”), pursuant to which the Executive was employed as the Senior Vice President, Quality and Operations Brands, of the Company ;

WHEREAS, the Company and the Executive desire to enter into this Agreement, which shall supersede the Prior Agreement in its entirety as of the Effective Date, except that the Company will pay the Executive the remainder of his sign-on bonus as stated in his Prior Agreement, to set forth the rights and obligations of the Parties hereto in respect of the Executive’s continued employment with the Company and, in connection therewith but for no remuneration, of Mallinckrodt plc, a public company with limited liability incorporated in Ireland (“Mallinckrodt” and, collectively with the Company and their respective subsidiaries and affiliates, the “Company Group”);

…

Open document
EX-10.7·10-Q·CIK 1567892·ACC 0001628280-26-034209·Filed May 13, 2026, 07:54 EDT